> But rayiner's entire point is about incentivizing R&D by allowing the collection of monopoly rents on patented drugs. I'm pointing to the generics as an illu

> But rayiner's entire point is about incentivizing R&D by allowing the collection of monopoly rents on patented drugs. I'm pointing to the generics as an illustration of Canada's pharmaceutical prices not being as controlled as people often think. (In fact, in Canada they're not controlled directly at all - they're simply pegged by law to other countries which set their own prices). I actually agree with rayiner's point about incentivizing R&D by allowing (temporary) collection of monopoly rents on patented drugs. I'm just saying that they should be collecting those monopoly rents from all countries that consume the drugs. Right now, they basically collect them only in the US, and allowing reimporting from other countries which respect US patent laws would ensure that all countries are contributing towards that in proportion to the amount that they actually consume the results of the R&D.